T. Else, A. C. Kim, A. Sabolch, V. M. Raymond, A. Kandathil et al., Adrenocortical carcinoma, Endocr. Rev, vol.35, pp.282-326, 2014.

G. Assié, E. Letouzé, M. Fassnacht, A. Jouinot, W. Luscap et al., Integrated genomic characterization of adrenocortical carcinoma, Nat. Genet, vol.46, pp.607-612, 2014.

E. M. Pinto, X. Chen, J. Easton, D. Finkelstein, Z. Liu et al., Genomic landscape of paediatric adrenocortical tumours, Nat. Commun, vol.6, 2015.

S. Zheng, A. D. Cherniack, N. Dewal, R. A. Moffitt, L. Danilova et al., Comprehensive pan-genomic characterization of adrenocortical carcinoma, Cancer Cell, vol.29, pp.723-736, 2016.

M. Doghman-bouguerra, V. Granatiero, S. Sbiera, I. Sbiera, S. Lacas-gervais et al., FATE1 antagonizes calcium-and drug-induced apoptosis by uncoupling ER and mitochondria, EMBO Rep, vol.7, pp.1264-1280, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02108682

A. W. Whitehurst, B. O. Bodemann, J. Cardenas, D. Ferguson, L. Girard et al., Synthetic lethal screen identification of chemosensitizer loci in cancer cells, Nature, vol.446, pp.815-819, 2007.

K. E. Maxfield, P. J. Taus, K. Corcoran, J. Wooten, J. Macion et al., Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer, Nat. Commun, vol.6, 2015.

Z. R. Gallegos, P. Taus, Z. A. Gibbs, K. Mcglynn, N. C. Gomez et al., EWSR1-FLI1 activation of the cancer/testis antigen FATE1 promotes Ewing sarcoma survival, Mol. Cell. Biol, vol.39, pp.138-157, 2019.

A. J. Simpson, O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old, Cancer/testis antigens, gametogenesis and cancer, Nat. Rev. Cancer, vol.5, pp.615-625, 2005.

X. Wei, F. Chen, K. Xin, Q. Wang, L. Yu et al., Cancer-testis antigen peptide vaccine for cancer immunotherapy: Progress and prospects, Transl. Oncol, vol.12, pp.733-738, 2019.

X. Y. Dong, Y. R. Su, X. P. Qian, X. A. Yang, X. W. Pang et al., Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients, Br. J. Cancer, vol.89, pp.291-297, 2003.

X. A. Yang, X. Y. Dong, H. Qiao, Y. D. Wang, J. R. Peng et al., Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues, Lab. Invest, vol.85, pp.205-213, 2005.

E. M. Pinto, C. Rodriguez-galindo, J. K. Choi, S. Pounds, Z. Liu et al., Prognostic significance of Major Histocompatibility Complex Class II expression in pediatric adrenocortical tumors: A St. Jude and Children's Oncology Group study, Clin. Cancer Res, vol.22, pp.6247-6255, 2016.

V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone et al., The immune landscape of cancer. Immunity, vol.48, pp.812-830, 2018.

P. Danaher, S. Warren, R. Lu, J. Samayoa, A. Sullivan et al., Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA), J. Immunother. Cancer, vol.6, 2018.

C. Fiorentini, S. Grisanti, D. Cosentini, A. Abate, E. Rossini et al., Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma, J. Oncol, 2019.

A. P. Fay, S. Signoretti, M. Callea, G. H. Teló, R. R. Mckay et al., Programmed death ligand-1 expression in adrenocortical carcinoma: An exploratory biomarker study, J. Immunother. Cancer, vol.3, issue.3, 2015.

L. Tourneau, C. Hoimes, C. Zarwan, C. Wong, D. J. Bauer et al., Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial, J. Immunother. Cancer, vol.6, p.111, 2018.

D. Cosentini, S. Grisanti, A. Dalla-volta, M. Laganà, C. Fiorentini et al., Immunotherapy failure in adrenocortical cancer: Where next?, Endocr. Connect, vol.7, pp.5-8, 2018.

I. Z. Parise, G. A. Parise, L. Noronha, M. Surakhy, T. D. Woiski et al., The prognostic role of CD8 + T lymphocytes in childhood adrenocortical carcinomas compared to Ki-67
URL : https://hal.archives-ouvertes.fr/inserm-02437545

E. Billon, P. Finetti, A. Bertucci, P. Niccoli, D. Birnbaum et al., PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma, Oncoimmunology, vol.8, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02509464

M. Fassnacht and S. Sbiera, , 2020.

E. Lalli and B. C. Figueiredo, Pediatric adrenocortical tumors: What they can tell us on adrenal development and comparison with adult adrenal tumors, Front. Endocrinol, vol.6, 2015.

M. Doghman, T. Karpova, G. A. Rodrigues, M. Arhatte, J. De-moura et al., Increased Steroidogenic Factor-1 dosage triggers adrenocortical cell proliferation and cancer, Mol. Endocrinol, vol.21, pp.2968-2987, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00172059

C. Ruggiero and E. Lalli, Impact of ACTH signaling on transcriptional regulation of steroidogenic genes, Front. Endocrinol, 2016.

M. A. Pianovski, L. R. Cavalli, B. C. Figueiredo, S. C. Santos, M. Doghman et al., SF-1 overexpression in childhood adrenocortical tumours, Eur. J. Cancer, vol.42, pp.1040-1043, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00172257

M. Q. Almeida, I. C. Soares, T. C. Ribeiro, M. C. Fragoso, L. V. Marins et al., Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults, J. Clin. Endocrinol. Metab, vol.95, pp.1458-1462, 2010.

S. Sbiera, S. Schmull, G. Assié, H. U. Voelker, L. Kraus et al., High diagnostic and prognostic value of Steroidogenic Factor-1 expression in adrenal tumors, J. Clin. Endocrinol. Metab, vol.95, pp.161-171, 2010.

C. Dähnrich, L. Komorowski, C. Probst, B. Seitz-polski, V. Esnault et al., Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy, Clin. Chim. Acta, vol.421, pp.213-218, 2013.

C. Zaghrini, B. Seitz-polski, J. Justino, G. Dolla, C. Payré et al., Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy, Kidney Int, vol.95, pp.666-679, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380896

L. Seifert, E. Hoxha, A. M. Eichhoff, G. Zahner, S. Dehde et al., The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy, J. Am. Soc. Nephrol, vol.29, pp.1536-1548, 2018.

T. Giordano, R. Kuick, T. Else, P. G. Gauger, M. Vinco et al., Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling, Clin. Cancer Res, vol.15, pp.668-676, 2009.

A. De-reyniès, G. Assié, D. S. Rickman, F. Tissier, L. Groussin et al., Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival, J. Clin. Oncol, vol.27, pp.1108-1115, 2009.

M. J. Demeure, K. E. Coan, C. S. Grant, R. A. Komorowski, E. Stephan et al., PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target, Surgery, vol.154, pp.1405-1416, 2013.

L. M. Mcshane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion et al., Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK), Br. J. Cancer, vol.93, pp.387-391, 2005.